Company Profile
Ibio Inc Stock Price, News & Catalysts
- Ticker:
- IBIO
- Exchange:
- AMEX
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.80 USD (-5.55%)
Close
Last updated: November 19, 2026
87.4M USD
Market cap
Why the stock is moving
As of Nov 19, 2026, IBIO closed down 5.55% at $0.8010. No new same-company headline was identified in the current news window.
Company overview
AI-Enabled Antibody Discovery
iBio develops antibodies using computational discovery and engineering platforms designed to improve target selection and molecular properties.
IBIO-600
IBIO-600 is a long-acting anti-myostatin antibody intended to preserve lean mass and improve body composition during obesity treatment.
Cardiopulmonary Expansion
The pipeline also includes a bispecific antibody program for pulmonary hypertension associated with heart failure with preserved ejection fraction.
Cardiometabolic Pipeline
iBio is building a portfolio of long-acting antibody therapies for obesity and related cardiometabolic diseases, led clinically by IBIO-600 and preclinically by IBIO-610.
Future catalysts
- IND-equivalent filing for IBIO-610 by the end of 2026.
- Initiation of first-in-human development for IBIO-610 in the first half of 2027.
- Interim single-ascending-dose Phase 1 data for IBIO-600 in the first quarter of 2027.
- Initiation of the multiple-ascending-dose portion of the IBIO-600 Phase 1 study in the first quarter of 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Ibio Inc (IBIO)?
Ibio Inc (IBIO) most recently closed at 0.80 USD, a -5.55% move versus the previous session.
What is the market cap of Ibio Inc (IBIO)?
Ibio Inc currently has a market capitalization of 87.4M USD on BioPharmSignal.
What does Ibio Inc do?
AI-Enabled Antibody Discovery iBio develops antibodies using computational discovery and engineering platforms designed to improve target selection and molecular properties. IBIO-600 IBIO-600 is a long-acting anti-myostatin antibody intended to preserve lean mass and improve body composition during obesity treatment. Cardiopulmonary Expansion The pipeline...
On which exchange is IBIO stock listed?
Ibio Inc (IBIO) is associated with AMEX, United States, Biopharma.
What is IBIO-600?
Interim single-ascending-dose Phase 1 data for IBIO-600 in the first quarter of 2027.
Which conditions is Ibio Inc targeting with IBIO-600?
Ibio Inc is associated with metabolic disease, obesity based on its company overview and current catalyst commentary.
How does Ibio Inc describe recent progress with IBIO-600?
Interim single-ascending-dose Phase 1 data for IBIO-600 in the first quarter of 2027.
What is IBIO-610?
Cardiometabolic Pipeline iBio is building a portfolio of long-acting antibody therapies for obesity and related cardiometabolic diseases, led clinically by IBIO-600 and preclinically by IBIO-610.
